BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong VK, Cheong-Lee C, Ford JAE, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy. World J Gastroenterol 2005; 11(34): 5392-5393 [PMID: 16149154 DOI: 10.3748/wjg.v11.i34.5392] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Piekarska A, Jozefowicz-korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin: Hipoacusia súbita en un paciente con síndrome de Turner y hepatitis crónica C tratado con interferón pegilado y ribavirina. International Journal of Audiology 2009;46:345-50. [DOI: 10.1080/14992020701261413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Jain S, Midha V, Sood A. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy. Indian J Gastroenterol 2011;30:239-40. [DOI: 10.1007/s12664-011-0126-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Waliszewska-Prosół M, Bladowska J, Ejma M, Fleischer-Stępniewska K, Rymer W, Sąsiadek M, Pawłowski T, Małyszczak K, Inglot M, Żelwetro A, Podgórski P, Knysz B. Visual and brainstem auditory evoked potentials in HCV-infected patients before and after interferon-free therapy - A pilot study. Int J Infect Dis 2019;80:122-8. [PMID: 30641198 DOI: 10.1016/j.ijid.2019.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Le V, Bader T, Fazili J. A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone. Nat Rev Gastroenterol Hepatol 2009;6:57-60. [DOI: 10.1038/ncpgasthep1317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Eser Karlidag G, Karlidag T, Demirdag K, Keles E. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011;38:312-8. [PMID: 21216118 DOI: 10.1016/j.anl.2010.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Pérez-Berná AJ, Pabst G, Laggner P, Villalaín J. Biophysical characterization of the fusogenic region of HCV envelope glycoprotein E1. Biochim Biophys Acta 2009;1788:2183-93. [PMID: 19698697 DOI: 10.1016/j.bbamem.2009.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
7 Mayet AY. Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin. Curr Ther Res Clin Exp 2007;68:271-7. [PMID: 24683217 DOI: 10.1016/j.curtheres.2007.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope 2021;131:1626-32. [PMID: 33491234 DOI: 10.1002/lary.29424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol 2007; 13(40): 5411-5412 [PMID: 17879419 DOI: 10.3748/wjg.v13.i40.5411] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
10 Casale M, Mazzarelli C, Vespasiani Gentilucci U, Potena M, Pappacena M, Faiella F, Galati G, Salvinelli F, Picardi A. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. Int J Immunopathol Pharmacol 2012;25:551-6. [PMID: 22697091 DOI: 10.1177/039463201202500229] [Reference Citation Analysis]
11 Chin-Loy K, Galaydh F, Shaikh S. Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection. Cureus 2016;8:e597. [PMID: 27335709 DOI: 10.7759/cureus.597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Zittoon RF, Madian YT, Alhennawi DEM, Nadeem HS. Cochlear Changes Caused by Peginterferon α-2b. J Interferon Cytokine Res 2018;38:311-6. [PMID: 30016180 DOI: 10.1089/jir.2018.0012] [Reference Citation Analysis]